Neurona Therapeutics is a company that strives to develop clinical-stage biotherapeutic treatments for neurological disorders with a focus on advancing regenerative cell therapy candidates. The company researches allogeneic therapies that come from stem cells harvested from donors. Neurona's proprietary therapy NRTX-1001 aims to reverse the effects of Alzheimer’s disease and other nervous system disorders. Neurona Therapeutics was founded by Arnold Kriegstein and Cory R. Nicholasin in 2008 and is headquartered in San Francisco, CA.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
02/08/2024 | Series E | $120MM | $xx.xx | $399.51MM | Alexandria Venture Investments, Berkeley Frontier Fund, Cormorant Asset Management, Euclidean Capital, Lyfe Capital, Schroders Capital, Sphera Biotech, Spur Capital Partners, Symbiosis, The Column Group, Ucb Ventures, Uc Investments, Viking Global Investors, Willett Advisors, Ysios Capital Partners | |
Price per Share
$xx.xx
Shares Outstanding
66,666,652
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Alexandria Venture Investments, Berkeley Frontier Fund, Cormorant Asset Management, Euclidean Capital, Lyfe Capital, Schroders Capital, Sphera Biotech, Spur Capital Partners, Symbiosis, The Column Group, Ucb Ventures, Uc Investments, Viking Global Investors, Willett Advisors, Ysios Capital Partners
|
||||||
03/19/2021 | Series D | $72.01MM | $xx.xx | $248.51MM | Alexandria Venture Investments, Ironfire Ventures, Sphera Fund Management, The Column Group, Ucb Ventures | |
Price per Share
$xx.xx
Shares Outstanding
40,004,768
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Alexandria Venture Investments, Ironfire Ventures, Sphera Fund Management, The Column Group, Ucb Ventures
|
||||||
11/18/2019 | Series C | $15.03MM | $xx.xx | $154.19MM | Undisclosed Investors | |
Price per Share
$xx.xx
Shares Outstanding
8,350,160
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Undisclosed Investors
|
||||||
02/08/2018 | Series B | $10.04MM | $xx.xx | $103.44MM | Undisclosed Investors | |
Price per Share
$xx.xx
Shares Outstanding
8,370,274
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Undisclosed Investors
|
||||||
12/01/2015 | Series A | $23.5MM | $xx.xx | $78.33MM | Alexsis De Raadt-St. James, The Column Group | |
Price per Share
$xx.xx
Shares Outstanding
26,111,111
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Alexsis De Raadt-St. James, The Column Group
|